KRAS and cancer: The KRAS oncogene is recurrently mutated in differenthuman cancers,45 and its mutational statusis associated with resistance to treatment with antibodies to EGFR.KRAS testing is now mandatory for the standard of care of colorectalcancers (CRCs), e.g., speeding up and facilitating this diagnosticactivity would be valuable for biotechnologists, molecular pathologists,medical oncologists, public decisors, and, obviously, patients.